New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland

Forensic Science International

Volumn 210, Issue 1-3, 2011, Pages 195-200

  Kriikku, Pirkko ^a   Wilhelm, Lars ^b   Schwarz, Olaf ^b   Rintatalo, Janne ^c  

^a Vita Laboratory   (Finland)

^b LADR GmbH MVZ Dr Kramer and Kollegen   (Germany)

^c National Bureau of Investigation Finland   (Finland)

Author keywords

Designer drugs; DUID; LC MS MS; MDPV; Pyrrolidinophenones

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; AMPHETAMINE; BENZODIAZEPINE; PYROVALERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CAR DRIVING; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRIVER; DRUG ABUSE; FINLAND; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; SCREENING TEST; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; TRAFFIC SAFETY;

EID: 79959534958     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.03.015     Document Type: Article

References (25)

1. Gardos G., Cole J.O. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr. Ther. Res. 1971, 13:631-635.
2. Deniker P., Loo H., Cuche H., Roux J.M. Abuse of pyrovalerone by drug addicts. Ann. Med. Psychol. 1975, 2:745.
3. Gibbons S., Zloh M. An analysis of the 'legal high' mephedrone. Bioorg. Med. Chem. Lett. 2010, 20:4135-4139.
4. Psychonaut WebMapping Research Group MDPV Report 2009, Institute of Psychiatry, King's College London, London, UK.
5. Ojanperä I.A., Heikman P.K., Rasanen I.J. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug Monit. 2011, 10.1097/FTD.0b013e318208b693.
6. Sauer C., Peters F.T., Haas C., Meyer M.R., Fritschi G., Maurer H. New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2009, 44:952-964.
7. Maurer H.H., Kraemer T., Springer D., Staack R.F. Chemistry, pharmacology, toxicology and hepatic metabolism of designer drugs of the amphetamine (ecstacy), piperazine, and pyrrolidinophenone types. Ther. Drug Monit. 2004, 26:127-131.
8. Brandt S.D., Wootton R.C.R., De Paoli G., Freeman S. The naphyrone story: the alpha or beta-naphtyl isomer?. Drug Test. Anal. 2010, 10.1002/dta.185.
9. F. Schifano, A. Albanese, S. Fergus, J.L. Stair, P. Deluca, O. Corazza, Z. Davey, J. Corkery, H. Siemann, N. Scherbaum, M. Farre', M. Torrens, Z. Demetrovics, A.H. Ghodse, Psychonaut Web Mapping, ReDNet Research Group, Mephedrone (4-methylcathinone; 'meow meow'): chemical, pharmacological and clinical issues, Psychopharmacology, doi:10.1007/s00213.010.2070.x.
10. Yohannan J.C., Bozenko J.S. The characterization of 3,4-methylenedioxypyrovalerone (MDPV). Microgram J. 2010, 7:12-15.
11. Westphal F., Junge T., Rösner P., Sönnichsen F., Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with α-pyrrolidinophenone structure. Forensic Sci. Int. 2009, 190:1-8.
12. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J. Mass Spectrom. 2010, 45:1426-1442.
13. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botrè F. Toxicological determination and in vitro metabolism of the new designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24:2706-2714.
14. Europol-EMCDDA Joint Report on a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone).
15. S. Fröhlich, E. Lambe, J. O'Dea, Acute liver failure following recreational use of psychotropic " head shop" compounds, Ir. J. Med. Sci., doi:10.1007/s11845.010.0636.6.
16. Elva åtalas i stor knarkhärva, Svenska Dagbladet, 22 October 2010, (accessed 23.11.2010). http://www.svd.se/nyheter/inrikes/elva-atalas-i-stor-knarkharva_5549347.svd.
17. Jones A.W. Age- and gender-related differences in blood amphetamine concentrations in apprehended drivers: lack of association with clinical evidence of impairment. Addiction 2007, 102:1085-1091.
18. Richtlinien der GTFCh zur Qualitätssicherung forensisch-toxikogischer Untersuchungen vom 01.06.2009.
19. Güssregen B., Schröfel S., Nauck M., Arndt T. Selective Reaction Monitoring (SRM) Daten von mehr als 900 Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen. Toxichem Krimtech 2008, 75(3):149-174.
20. Schröfel S., Güssregen B., Werle A., Nauck M., Arndt T. Selective Reaction Monitoring (SRM) Daten von Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen - Teil 2. Toxichem Krimtech 2010, 77(2):117-136.
21. DIN EN ISO/IEC 32645, 1994.
22. Karjalainen K.K., Lintonen T.P., Impinen A.O., Lillsunde P.M., Ostamo A.I. Poly-drug findings in drugged driving cases during 1977-2007. J. Subst. Abuse 2010, 15:143-156.
23. Wohlfarth A., Weinmann W. Bioanalysis of new designer drugs. Bioanalysis 2010, 2:965-979.
24. EMCDDA-Europol 2009 Annual Report on the Implementation of Council Decision 2005/387/JHA.
25. Jones A.W., Holmgren A., Kugelberg F.C. Driving under the influence of central stimulant amines: age and gender differences in concentrations of amphetamine, methamphetamine and ecstasy in blood. Traffic Inj. Prev. 2005, 6:317-322.